Navigation Links
Onyx Pharmaceuticals Reports Second Quarter 2011 Financial Results
Date:8/3/2011

exavar being our only approved product; we may never receive marketing approval for carfilzomib; competition; failures or delays in our clinical trials; dependence on our collaborative relationship with Bayer; if approved, we may be unsuccessful in launching, maintaining adequate supply of or obtaining reimbursement for carfilzomib; market acceptance and the rate of adoption of our products; pharmaceutical pricing and reimbursement pressures; serious adverse side effects, if they are associated with Nexavar or carfilzomib; government regulation; possible failure to realize the anticipated benefits of business acquisitions or strategic investments; protection of our intellectual property; the indebtedness incurred through the sale of our 4.0% convertible senior notes due 2016; and product liability risks. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission, under the heading "Risk Factors" for a more detailed description of these and other risks. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

(See attached tables)ONYX PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share amounts)(unaudited)Three Months EndedSix Months EndedJune 30, June 30, 2011201020112010Revenue: Revenue from collaboration agreement

$
7,956$
8,773$   135,101$   131,676Total revenue

67,95668,773135,101131,676Operating expenses:Research and development (1) (2)63,04543,251125,53886,826Selling, general and administrative (1)38,23626,64772,70751,368Contingent consideration

5,75592,03717,25095,485Leas
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Access Pharmaceuticals Adds Blue Cross Blue Shield of Hawaii, SummaCare and AvMed to MuGard Payer List
2. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects?
3. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
4. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
5. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
6. MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
7. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
9. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
10. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
11. Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Echo Therapeutics, Inc. (NASDAQ: ... on skin permeation, continuous glucose monitoring and associated ... has been appointed Chief Executive Officer effective ... 20 years of experience in the medical device, ... served as Vice President, Business Development, Otsuka Pharmaceuticals as ...
(Date:12/24/2014)... 2014   Assurex Health, a personalized medicine ... providers for behavioral health and chronic pain conditions, ... in equity financing from new and existing investors, ... and Chief Executive Officer. The financing ... Assurex Health,s GeneSight ®  products.  GeneSight,s ...
(Date:12/24/2014)... and RALEIGH, N.C. , Dec. 23, ... International plc (NASDAQ: ENDP ) (TSX: ENL), ... ) announced today that they have submitted a New ... the U.S. Food and Drug Administration (FDA).  Buprenorphine HCl ... pain severe enough to require daily, around-the-clock, long-term opioid ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... Ind., Oct. 6 Hill-Rom Holdings, Inc. (NYSE: ... unanimously approved enhancements to the Company,s corporate governance ... majority voting in uncontested elections. The Board ... a majority voting standard for the election of directors in ...
... 6 CareFusion (NYSE: CFN ), a new ... rankings by independent market research firms for two of ... named number one in user satisfaction ratings in MD ... the third consecutive quarter; and CareFusion,s MedMined(TM) Services received ...
Cached Medicine Technology:Hill-Rom Announces Corporate Governance Enhancements 2Hill-Rom Announces Corporate Governance Enhancements 3Hill-Rom Announces Corporate Governance Enhancements 4CareFusion Earns Top Ranking in MD Buyline and KLAS Reports 2CareFusion Earns Top Ranking in MD Buyline and KLAS Reports 3
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
(Date:12/25/2014)... The short film “Color of Honor” by ... of a true 9/11 hero, Welles Remy Crowther. It has ... 24 hours of Nuremberg International Short Film Festival and the ... Actress, screenwriter and director Luciana Lagana plays the mother ... her husband, Gregory Graham - Graham plays a ...
(Date:12/25/2014)... December 25, 2014 Recently, LunaDress.co.uk has updated its ... and related accessories. Now, all of the models at LunaDress.co.uk come ... a groom lifts the wedding veil can turn out to be ... charm. A wedding veil can always bring surprise to a wedding. ... on how to choose veils for a big day . ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... be closing in on a "fountain of youth" drug that ... of older adults, a new study suggests. Seniors received ... drug that targets a genetic signaling pathway linked to aging ... The experimental medication, a version of the ...
(Date:12/25/2014)... Newton, North Carolina (PRWEB) December 25, 2014 ... a North Carolina Retirement Community, recently showed their ... and girls of the Catawba County Parenting Network- ... meal, the 10 children gathered around the largest ... community to open presents purchased by residents of ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2
... and Eliza Hall,Institute of Medical Research (WEHI) announced ... a leading biotechnology company,based in South San Francisco ... to discover new anti-cancer drugs., "This exciting ... field may increase the chance of translating basic ...
... growing away-from-home ... washroom ... announced it has signed a definitive agreement to acquire,Technical Concepts ... hygiene systems for several high-growth,segments of the away-from-home ("AFH") washroom ...
... High-Performance ... Academia, SOUTHPOINTE, Pa., Feb. 27 ANSYS, ... simulation software and technologies,designed to optimize product development ... and Technology Information (KISTI), one of,the world,s largest ...
... To Enhance Body, Mind & Spirit, VAIL, ... approach to healthcare, Next Step(R) Institute of Integrative,Medicine, ... Colorado, has recently announced its 2008 series of ... Next Step(R) Institute Wellness Weeks are six-night, five-day ...
... popular among,30-somethings who don,t want to look a ... somethings who,d like to look 40 again, StriVectin(R)-HS,Hydro-Thermal ... as the only,"great" beauty serum for older complexions ... just published "beauty serum" ranking., (Photo: ...
... Two emergency care training,organizations acquired by a single ... created parent company at the helm -- and aggressive ... The Riverside Company, which purchased the American Safety & ... over a year,ago, recently created parent company, the Health ...
Cached Medicine News:Health News:Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs 2Health News:Newell Rubbermaid to Grow Commercial Products Platform with Agreement to Acquire Technical Concepts 2Health News:Newell Rubbermaid to Grow Commercial Products Platform with Agreement to Acquire Technical Concepts 3Health News:Newell Rubbermaid to Grow Commercial Products Platform with Agreement to Acquire Technical Concepts 4Health News:KISTI Selects ANSYS as a Key Supplier in Engineering Simulation 2Health News:KISTI Selects ANSYS as a Key Supplier in Engineering Simulation 3Health News:KISTI Selects ANSYS as a Key Supplier in Engineering Simulation 4Health News:Next Step(R) Institute of Integrative Medicine, Inc. Takes Wellness to a New Level With 2008 Series of Wellness Weeks 2Health News:Next Step(R) Institute of Integrative Medicine, Inc. Takes Wellness to a New Level With 2008 Series of Wellness Weeks 3Health News:Next Step(R) Institute of Integrative Medicine, Inc. Takes Wellness to a New Level With 2008 Series of Wellness Weeks 4Health News:America's StriVectin the Only 'Great' Serum for Mature, Aging Complexions, Says Leading British Newspaper 2Health News:New Health & Safety Institute Creates Extensive, Centralized Resource for Emergency Care Training 2
The LM-990A is the most completely automatic lensemeter ever created. It even measured monocular and binocular PD automatically....
... The EyeSys Vista brings new ... while retaining the quality and excellence ... products. The Vista offers eyecare practitioners ... for corneal topography that utilizes the ...
... has added the NEW Evolution electronic refractor ... The Evolution offers the convenience of a ... well below other automated refraction systems. The ... the refraction process through the handheld remote ...
Uniquely designed, the wheelchair table has dual purposes. Not only does it add a modern look to any office, it is also a heavy-duty table that will support multiple instruments, and/or easily accomm...
Medicine Products: